Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00198276
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : October 3, 2017
Information provided by (Responsible Party):
Inovio Pharmaceuticals

Brief Summary:
The purpose of the study is to study the safety and efficacy of MedPulser Electroporation with bleomycin treatment of cutaneous and subcutaneous foci of cancer.

Condition or disease Intervention/treatment Phase
Cancer Combination Product: MedPulser Electroporation with bleomycin Phase 4

Detailed Description:

Electroporation therapy (EPT) is a tumor-specific ablative treatment modality with the potential to manage local tumors without the potentially undesirable side effects of systemic chemotherapy agents or radiotherapy. Surgical resection of cutaneous lesions may lead to significant organ dysfunction and/or permanent disfigurement requiring reconstructive surgery (i.e. nose, eye area, ears, medial canthus, nasolabial fold, lip, scalp, etc.). In contrast, electroporation therapy may offer equivalent disease control to conventional surgery with a lessened need for reconstructive surgery.

The ability to ablate local cutaneous lesions with the MedPulser® System when used in conjunction with intralesional Bleomycin is an important new treatment for the local management of recurrent Basal Cell Carcinoma (BCC), recurrent Squamous Cell Carcinoma (SCC), Melanoma, Adenocarcinoma (i.e. local recurrence of breast cancer), Merkel Cell Carcinoma and Cutaneous Lymphoma and other solid tumors with symptomatic subcutaneous recurrences and provides an alternative treatment option to subjects who:

  1. have failed standard treatments; or who
  2. are unwilling or unsuitable to undergo conventional surgical excision or radiation.

EPT with Bleomycin spares normal tissue and its use in local disease management may preserve organ function and/or appearance relative to surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Intervention Model: Single Group Assignment
Intervention Model Description: MedPulser Electroporation with Belomycin
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer
Study Start Date : February 2004
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bleomycin
Bleomycin 4.0 U/mL at dose of 1 U/cm^3 of treatment area; Medpulser EP
Combination Product: MedPulser Electroporation with bleomycin
The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.

Primary Outcome Measures :
  1. Local tumor control [ Time Frame: 6 Months ]

Secondary Outcome Measures :
  1. Pharmacoeconomic factors (e.g. hospital costs, extent of medical interventions, medication use) [ Time Frame: 24 Months ]
  2. MedPulser instrument and applicator performance [ Time Frame: 6 Months ]
  3. Adverse events [ Time Frame: 6 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The presence of recurrent SCC, recurrent BCC, melanoma, adenocarcinoma (i.e., local recurrence of breast cancer), merkel cell carcinoma, cutaneous lymphoma, other subcutaneous solid tumors, or primary cutaneous tumors must be confirmed by histological examination of a tissue (e.g., biopsy) sample obtained within 1 month prior to a patient signing the informed consent form for the study.
  2. Total volume of disease treated will require a dose of bleomycin sulfate less than 80 units.
  3. Tumors and margins must be completely accessible to intralesional bleomycin injections and the EPT applicator electrodes.
  4. Age: 18 years or older.
  5. Male or female.
  6. Men and women of childbearing potential must be using physician prescribed contraceptive methods while undergoing protocol related therapy.
  7. Baseline performance status: ECOG 0-2

    • Grade 0: Fully active, able to carry on all pre-disease performance without restriction.
    • Grade 1: Restricted in a physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
    • Grade 2: Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours.
  8. Life expectancy of at least 6 months.
  9. Sign a written Informed Consent prior to receiving any study procedures or treatments.

Exclusion Criteria:

  1. Subjects with tumors suspected of involving a 50% or greater encasement of a blood vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
  2. Subjects with tumors having bone invasion.
  3. Subjects with hypersensitivity to bleomycin.
  4. Subjects who have received or will exceed a total lifetime dose of bleomycin greater than 400 units.
  5. Subjects with a significant history of emphysema or pulmonary fibrosis.
  6. Subjects with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off.
  7. Subjects with a history of uncontrolled cardiac arrhythmia.
  8. Women who are pregnant, or are nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00198276

Layout table for location information
United States, California
Inovio Biomedical Corporation
San Diego, California, United States, 92121
Sponsors and Collaborators
Inovio Pharmaceuticals
Layout table for investigator information
Study Chair: Paul Goldfarb, MD Inovio Pharmaceuticals

Layout table for additonal information
Responsible Party: Inovio Pharmaceuticals Identifier: NCT00198276    
Other Study ID Numbers: EU-CCBE-2003
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: October 3, 2017
Last Verified: September 2017
Keywords provided by Inovio Pharmaceuticals:
Cutaneous or subcutaneous cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Antibiotics, Antineoplastic
Antineoplastic Agents